Skip to main content
Top
Published in: Drugs & Aging 8/2018

01-08-2018 | Current Opinion

How Common is Statin Use in the Oldest Old?

Authors: Wade Thompson, Anton Pottegård, Jesper Bo Nielsen, Peter Haastrup, Dorte Ejg Jarbøl

Published in: Drugs & Aging | Issue 8/2018

Login to get access

Abstract

There is a lack of evidence surrounding the efficacy of statins in the oldest old (≥ 80 years of age). As such, there is controversy surrounding use of statins in this population. We sought to evaluate the prevalence of statin use in the oldest old worldwide to understand the scope of this issue. We searched PubMed and grey literature over the last 5 years. Studies had to report the prevalence of statin use in adults ≥ 80 years of age. The first author performed screening and extracted data. Our search produced 1870 hits; 14 articles were considered eligible. We found three studies of nursing home residents, eight studies of community-dwelling patients and three studies in the combined population (i.e., both community-dwelling patients and nursing home residents). The prevalence of statin use ranged from 17 to 39% in nursing home residents, 12 to 59% for community-dwelling patients and 18 to 45% in combined populations. Beyond age 80 years, the prevalence of statin use appeared to decrease with advancing age. Statin use was more common as secondary prevention compared with primary prevention. The prevalence of statin use in the oldest old has increased over recent decades. The increase in prevalence appears to be more pronounced in the oldest old compared with younger old, as reported by two studies. Statins are widely used in the oldest old despite the lack of evidence in this population. Given how common statin use is in the oldest old, clinical evidence surrounding their efficacy in this group is urgently needed to guide appropriate use and shared decision-making.
Appendix
Available only for authorised users
Literature
1.
go back to reference Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades A. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013;20(4):641–57. https://doi.org/10.1177/2047487313480435.CrossRefPubMed Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades A. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. Eur J Prev Cardiol. 2013;20(4):641–57. https://​doi.​org/​10.​1177/​2047487313480435​.CrossRefPubMed
22.
go back to reference Proulx J, Hunt J. Drug use among seniors on public drug programs in Canada, 2012. Healthc Q. 2015;18(1):11–3.CrossRefPubMed Proulx J, Hunt J. Drug use among seniors on public drug programs in Canada, 2012. Healthc Q. 2015;18(1):11–3.CrossRefPubMed
Metadata
Title
How Common is Statin Use in the Oldest Old?
Authors
Wade Thompson
Anton Pottegård
Jesper Bo Nielsen
Peter Haastrup
Dorte Ejg Jarbøl
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 8/2018
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-018-0567-x

Other articles of this Issue 8/2018

Drugs & Aging 8/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine